http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2855499-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c5e77c181522ee1fd44df1ae5ac2196 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D271-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D249-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 |
| filingDate | 2015-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09e7a4e3db509e42a0f133f2160e47db http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_780831b7100603451417e9c916743e57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80f3aef6f0601425da5d67bd3be69f10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfe087e774db9ac921b2bddf650a70b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95ee71c9b9583a206d2570257d2cca70 |
| publicationDate | 2021-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2855499-T3 |
| titleOfInvention | 1,2-substituted cyclopentanes as orexin receptor antagonists |
| abstract | A compound of formula (I) where R1 represents a 6-membered heteroaryl group optionally substituted by at least one substituent selected from halogen, cyano, hydroxyl, C3-C6 cycloalkyl, C1-C3 alkyl, C1-C3 alkoxy, C1- alkoxycarbonyl C3, C1-C3 alkoxycarbylamino, C1-C3 haloalkyl, C1-C3 haloalkoxy, cycloalkylamino -NR4R5, C3-C6, C1-C3 alkylcarbonyloxy, C1-C3 alkylcarbonylamino, suflonamido, C1-C3 alkylsulfonyl, C1-C3 alkylsulfonylamino O) NR6R7; L represents a bond, CH2, O or NR12; Ra represents a hydrogen atom or a C1-C3 alkyl or C1-C3 haloalkyl group; Rb represents a hydrogen atom or a C1-C3 alkyl or C1-C3 haloalkyl group; X represents CH2, CHF or CF2; R2 represents a hydrogen atom or a C1-C6 alkyl or C3-C6 cycloalkyl group; R3 represents a phenyl group or a 5- or 6-membered heteroaryl group, all optionally substituted by at least one substituent independently selected from halogen, hydroxyl, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 hydroxyalkyl, C1 alkoxy -C3, C1-C3 haloalkoxy, C2-C4 alkenyl, C1-C3 alkylcarbonyloxy, C1-C3 alkoxycarbonyl, cycloalkyl -NR8R9, -C (O) NR1 ° R11, C3-C6, C3-C6 cycloalkyloxy, C3-C6 cycloalkylmethyl or a 5- or 6-membered heteroaryl group, the heteroaryl group itself being optionally substituted by at least one substituent independently selected from C1-C6 alkyl, C1-C6 alkoxy, and C1-C6 haloalkoxy; R4 and R5 each independently represent a hydrogen atom or a C1-C3 alkyl or C3-C6 cycloalkyl group, or R4 and R5 may form, together with the nitrogen atom to which they are attached, a saturated heterocyclic ring of 4-7 membered optionally substituted by at least one substituent independently selected from halogen, hydroxyl, and C1-C3 alkoxy; R6 and R7 each independently represent a hydrogen atom or a C1-C3 alkyl or C3-C6 cycloalkyl group, or R6 and R7 may form, together with the nitrogen atom to which they are attached, a saturated heterocyclic ring of 4-7 membered optionally substituted by at least one substituent independently selected from halogen and hydroxyl; R8 and R9 each independently represent a hydrogen atom or a C1-C3 alkyl or C3-C6 cycloalkyl group, or R8 and R9 may form, together with the nitrogen atom to which they are attached, a saturated heterocyclic ring of 4-7 membered optionally substituted by at least one substituent independently selected from halogen, hydroxyl, and C1-C3 alkoxy; R1 ° and R11 each independently represent a hydrogen atom or a C1-C3 alkyl group C3-C6 cycloalkyl, or R1 ° and R11 can form, together with the nitrogen atom to which they are attached, a saturated heterocyclic ring 4-7 membered optionally substituted by at least one substituent independently selected from halogen and hydroxyl; and R12 represents a hydrogen atom, a methyl group, or a C2-C3 alkylene chain that joins R1 to form a 5- or 6-membered ring; or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2014-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 859.